Aromatase Inhibitors Market Snapshot
“The Aromatase Inhibitors Market is estimated to increase at a CAGR of 5.45% from $ 15.02 billion in 2023 to $ 21.34 Billion by 2030.”
Aromatase inhibitors are drugs used to treat postmenopausal women, men with breast cancer, and gynecomastia. They can also be used off-label to reduce estrogen conversion when testosterone is supplemented.
Aromatase inhibitors inhibit the aromatization step in estrogen synthesis, converting androgen precursors like testosterone to phenols. Hormone-positive breast and ovarian cancers rely on estrogen for growth, so AIs block estrogen production or estrogen's action on receptors. They may also be used for chemoprevention in high-risk women.
Aromatase inhibitors prevent the conversion of androgens into estrogens through aromatization, which stimulates breast tissue. Decreased estrogen production suppresses breast tumor recurrence. In premenopausal women, ovaries are the main source of estrogen, while postmenopausal women's estrogen is primarily produced in peripheral tissues and a few CNS sites in the brain.
Estrogen is produced and acts locally in these tissues, but any circulating estrogen that has systemic estrogenic effects in men and women is caused by estrogen escaping local metabolism and spreading to the circulatory system.
What are the potential risks and side effects of aromatase inhibitors?
aromatase inhibitors often cause menopausal symptoms like hot flashes, night sweats, and vaginal dryness, along with muscle and joint pain, which can lead some women to discontinue their medication.
AIs, unlike tamoxifen and raloxifene, can accelerate bone thinning, leading to osteoporosis. Doctors advise checking bone density before starting AIs. AIs may also increase cholesterol, especially in women with pre-existing heart disease, increasing the risk of heart problems. Therefore, careful consideration is advised before using AIs.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/aromatase-inhibitors-market-54609
The process of taking an aromatase inhibitor involves consuming a liquid solution that inhibits the enzyme that produces the enzyme.
Aromatase inhibitors are daily pills used to treat breast cancer. Some individuals may start treatment with an aromatase inhibitor or tamoxifen. Most people take them for five years before stopping if no recurring or new cancer is found. After five years, remission may be achieved if no cancer symptoms or tests are present.
Growth Drivers
Hormone receptor-positive breast cancer is on the rise globally, increasing the need for effective treatment options like aromatase inhibitors.
The medical community and patients are increasingly recognizing the advantages of aromatase inhibitors in enhancing patient outcomes and reducing the risk of cancer recurrence.
Pharmaceutical companies are investing heavily in research and development to create new and improved aromatase inhibitors with enhanced efficacy and reduced side effects.
Market Restraints
Aromatase inhibitors can be expensive, making them less accessible to patients in areas with limited healthcare resources and insurance coverage.
Aromatase inhibitors, like any medication, may have potential side effects like joint pain, osteoporosis, and increased cardiovascular risks, which may limit their use in certain patients.
The patent expiration of certain aromatase inhibitors has led to the introduction of generic versions, resulting in increased price competition and reduced revenue for original drug manufacturers.
Aromatase Inhibitors Market Segment Analysis
Two types of aromatase inhibitors have been approved for treating breast cancer.
Exemestane, an irreversible steroidal inhibitor, forms a permanent and deactivating bond with the aromatase enzyme.
Nonsteroidal inhibitors like Arimidex and Femara, which are nonsteroidal drugs, work by reversibly competing with estrogen synthesis.
Competitive Landscape of the Aromatase Inhibitors Market Analysis
- Pfizer Inc
- AstraZeneca
- ANI Pharmaceuticals
- Bristol-Myers Squibb Company
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical Industries Ltd
- Zydus Cadila
- Cipla Inc.
- Amneal Pharmaceuticals LLC
- Glenmark Pharmaceuticals Limited
- Fresenius Kabi AG
- Mayne Pharma Group Limited
- Mylan N.V.
- Novartis AG.
- Vintage Labs
- Reddy’s Laboratories Ltd
- Jiangsu Hengrui Medicine Co.
- Novo Nordisk A/S
- Otsuka America Pharmaceutical
- WOCKHARDT
New Developments in Aromatase Inhibitors Market
Breaking News, 12 June 2023 Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer
AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with Faslodex (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.
The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is during the fourth quarter of 2023.
Breaking News, May 04, 2022 Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022
May 4, 2022 – Pfizer Inc. announced the presentation of real-world evidence demonstrating an associated benefit for patients treated with IBRANCE® (palbociclib) in combination with an aromatase inhibitor (AI), as compared to AI alone, in the first-line setting, at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 Congress. This retrospective cohort study is a large comparative effectiveness study of 2,888 hormones receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) patients evaluating IBRANCE in combination with AI compared to AI alone and demonstrated an associated improved overall survival (OS) in post-menopausal women and in men with HR+, HER2- mBC treated in routine clinical practice in the United States.
Regional Analysis
The global aromatase inhibitors drug market is primarily dominated by North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads due to high breast cancer prevalence, established healthcare infrastructure, and favorable reimbursement policies. Asia Pacific is expected to experience significant growth due to rising breast cancer incidence and improved healthcare infrastructure.
Segments Covered in the Aromatase Inhibitors Market Report
Drug
- Formestane
- Fadrozole
- Exemestane
- Anastrozole
- Letrozole
- Others
Mode of action
- Selective Inhibitors
- Non-Selective Inhibitors
Route of Administration
The above information has been provided for the following regions and countries:
North America
Europe
- UK
- Germany
- France
- Italy
- Russia
Asia Pacific
- China
- India
- Japan
- South Korea
Latin America
MEA
- UAE
- Saudi Arabia
- South Africa
Frequently Asked Questions
What is the expected growth rate of the Aromatase Inhibitors market over the next 7 years?
The Aromatase Inhibitors Market is estimated to increase at a CAGR of 5.45% from $ 15.02 billion in 2023 to $ 21.34 Billion by 2030.
Who are the major players in the Aromatase Inhibitors market and what is their market share?
Pfizer Inc,AstraZeneca,ANI Pharmaceuticals,Bristol-Myers Squibb Company,Hikma Pharmaceuticals PLC,Teva Pharmaceutical Industries Ltd,Zydus Cadila,Cipla Inc.,Amneal Pharmaceuticals LLC,Glenmark Pharmaceuticals Limited,Fresenius Kabi AG,Mayne Pharma Group Limited,Mylan N.V.,Novartis AG.,Vintage Labs,Dr. Reddy’s Laboratories Ltd,Jiangsu Hengrui Medicine Co.,Novo Nordisk A/S,Otsuka America Pharmaceutical,WOCKHARDT, are prominent players operating and dominating in the market.
What is the demand projection for Aromatase Inhibitors by 2030?
Demand for Aromatase Inhibitors is projected to reach a market value of US$ 21.34 Billion by 2030-end.
What is the sales growth projection for Aromatase Inhibitors?
Revenue from sales of Aromatase Inhibitors is projected to increase at a CAGR of 5.45% through 2030.
1.SUMMARY
1.1. Aromatase Inhibitors Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Aromatase Inhibitors
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Aromatase Inhibitors
3.7 Challenges associated with Aromatase Inhibitors
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Aromatase Inhibitors: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Aromatase Inhibitors: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Aromatase Inhibitors: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Aromatase Inhibitors: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Aromatase Inhibitors
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Pfizer Inc
- AstraZeneca
- ANI Pharmaceuticals
- Bristol-Myers Squibb Company
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical Industries Ltd
- Zydus Cadila
- Cipla Inc.
- Amneal Pharmaceuticals LLC
- Glenmark Pharmaceuticals Limited
- Fresenius Kabi AG
- Mayne Pharma Group Limited
- Mylan N.V.
- Novartis AG.
- Vintage Labs
- Reddy’s Laboratories Ltd
- Jiangsu Hengrui Medicine Co.
- Novo Nordisk A/S
- Otsuka America Pharmaceutical
- WOCKHARDT
